Advertisement
Canada markets open in 7 hours 19 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7305
    +0.0008 (+0.10%)
     

  • CRUDE OIL

    82.91
    +0.10 (+0.12%)
     

  • Bitcoin CAD

    87,949.75
    -3,287.51 (-3.60%)
     

  • CMC Crypto 200

    1,390.15
    +7.57 (+0.55%)
     

  • GOLD FUTURES

    2,330.80
    -7.60 (-0.33%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,419.25
    -245.25 (-1.39%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,649.00
    -811.08 (-2.11%)
     

  • CAD/EUR

    0.6816
    -0.0003 (-0.04%)
     

Exact Sciences Posted 52.2% Returns in the Last Month

Margaret Patrick
Updated
Exact Sciences Posted 52.2% Returns in the Last Month

Exact Sciences (EXAS) stock has reported a 67.1% rise in the last month, from $49.93 on August 10 to $75.99 on September 10. Its performance was mainly due to its collaboration with Pfizer (PFE) for the increasing adoption of Exact Sciences’ Cologuard non-invasive stool DNA test for colorectal cancer screening in the United States. According to the collaboration announced on August 22, Pfizer will actively participate in promoting Cologuard until 2021.

Continue reading